CompanyGraph
Guangdong Lifestrong Pharmaceutical Co., Ltd.
301111 · SZSE · China
wnqzy.com.cnFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.24%
Annual Rate
CNY 0.05Paid unknown
Payout Ratio
91.7%High
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.63BCNY538.47M · vs all stocks (USD)
Revenue (TTM)
310.01MCNY46.04M · vs all stocks (USD)
Profit Margin
-1.40%Beta
0.9360xvs all stocks
52-Week Change
27.91%vs all stocks
Forward Annual Dividend Yield
0.24%vs all stocks
Market Capitalization
3.63BCNY538.47M · vs all stocks (USD)
Enterprise Value
3.13BCNY465.29M · vs all stocks (USD)
Price to Sales (TTM)
12.31xPrice to Book (MRQ)
5.11xEnterprise to Revenue
10.11xGross Margin
52.59%Profit Margin
-1.40%Operating Margin
-7.52%Return on Assets (TTM)
-1.25%Return on Equity (TTM)
-1.14%Revenue (TTM)
310.01MCNY46.04M · vs all stocks (USD)
Revenue per Share (TTM)
2.07CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-6.50%Gross Profit (TTM)
181.64MCNY26.98M · vs all stocks (USD)
EBITDA (TTM)
15.34MCNY2.28M · vs all stocks (USD)
Net Income (TTM)
-4.35MCNY-646.60K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.54%Operating Cash Flow (TTM)
17.47MCNY2.59M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-281.70MCNY-41.84M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0500CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
0.24%vs all stocks
Trailing Annual Dividend Rate
0.0500CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.24%vs all stocks
Payout Ratio
91.66%Minority Interest (Equity)
531.22KCNYFY2025 · Dec 31, 2025Revenue
314.64MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
123.78MCNYFY2025 · Dec 31, 2025Gross Profit
190.86MCNYFY2025 · Dec 31, 2025Operating Income
-18.05MCNY-2.68M · vs all stocks (USD)
Pre-tax Income
-9.76MCNYFY2025 · Dec 31, 2025Income Tax Expense
-626.78KCNYFY2025 · Dec 31, 2025Net Income
-9.13MCNYFY2025 · Dec 31, 2025EBIT
-6.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
15.34MCNYFY2025 · Dec 31, 2025Research & Development
8.49MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
140.25MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.53MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.00MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.06MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
149.63MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
149.63MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.13MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.64MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-33.31MCNYFY2025 · Dec 31, 2025Free Cash Flow
-42.48MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
142.64MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.13MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.02MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-38.00MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.80MCNYFY2025 · Dec 31, 2025Capital Expenditures
-9.17MCNYFY2025 · Dec 31, 2025Net Acquisitions
13.08MCNYFY2025 · Dec 31, 2025Purchase of Investments
-378.05MCNYFY2025 · Dec 31, 2025Sale of Investments
352.46MCNYFY2025 · Dec 31, 2025Other Investing Activity
543.97KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-21.14MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.00MCNYFY2025 · Dec 31, 2025Other Financing Charges
2.11MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.89MCNYFY2025 · Dec 31, 2025Shares Outstanding
160.00MSharesUpdated Aug 20, 2026Float Shares
90.20MSharesUpdated Aug 20, 2026% Held by Insiders
46.69%vs all stocks
% Held by Institutions
6.39%vs all stocks
Total Cash (MRQ)
201.90MCNY29.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.26CNYUpdated Aug 20, 2026Total Debt (MRQ)
45.13MCNY6.70M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0601xCurrent Ratio (MRQ)
6.48xBook Value per Share (MRQ)
4.67CNYUpdated Aug 20, 2026Total Assets
894.13MCNY132.80M · vs all stocks (USD)
Total Current Assets
700.90MCNYFY2025 · Dec 31, 2025Total Liabilities
142.91MCNYFY2025 · Dec 31, 2025Total Non-current Assets
193.23MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
40.63MCNYFY2025 · Dec 31, 2025Total Current Liabilities
102.28MCNYFY2025 · Dec 31, 2025Cash
142.78MCNYFY2025 · Dec 31, 2025Cash Equivalents
351.95KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
143.14MCNYFY2025 · Dec 31, 2025Other Short-term Investments
77.59MCNYFY2025 · Dec 31, 2025Accounts Receivable
76.60MCNYFY2025 · Dec 31, 2025Inventory
77.31MCNYFY2025 · Dec 31, 2025Accounts Payable
63.72MCNYFY2025 · Dec 31, 2025Short-term Debt
5.24MCNYFY2025 · Dec 31, 2025Other Current Liabilities
868.67KCNYFY2025 · Dec 31, 2025Long-term Debt
40.24MCNYFY2025 · Dec 31, 2025Common Stock (Book)
160.00MCNYFY2025 · Dec 31, 2025Retained Earnings
149.68MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
751.22MCNY111.57M · vs all stocks (USD)
52-Week Low
15.08CNYUpdated Aug 20, 202652-Week High
31.36CNYUpdated Aug 20, 202652-Week Change
27.91%vs all stocks
Beta
0.9360xvs all stocks
50-Day MA
22.66CNYUpdated Aug 20, 2026200-Day MA
21.80CNYUpdated Aug 20, 2026Avg 10-Day Volume
5.83MSharesUpdated Aug 20, 2026Avg 30-Day Volume
5.42MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.0300CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.53Profit Margin: -0.01
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule